Purification of Recombinant Human B‐Domain‐Deleted Factor VIII Using Anti‐Factor VIII Monoclonal Antibody Selected by the Surface Plasmon Resonance Biosensor

The surface plasmon resonance (SPR) biosensor measures the real‐time kinetics of noncovalent interaction between a receptor and its ligand. Monoclonal antibodies (mAbs) against recombinant factor VIII (rFVIII) were screened from 127 mAb candidates using the SPR biosensor for the purpose of affinity purification of rFVIII. Each mAb showed a different association and dissociation capacity for rFVIII at each buffer condition. One mAb, F8–38, was selected for immunopurification of rFVIII. To characterize the selected mAb F8–38, the immunopurification results on the anti‐FVIII mAb F8–38 affinity gel and the anti‐von Willebrand factor (vWF) mAb affinity gel were studied. Immunopurification by the anti‐vWF affinity gel showed a lower binding capacity of rFVIII and resulted in low purification efficiency. On the other hand, immunopurification by the anti‐FVIII affinity gel exhibited a 3.5‐fold binding capacity and a 2‐fold purification efficiency compared to those of the anti‐vWF affinity gel. The amounts of proteins and DNAs derived from host cells and mouse IgGs derived from the affinity matrix in the affinity eluate were similar to those of the anti‐vWF affinity gel. In conclusion, the SPR method of immunopurification is a useful technology in the screening of mAbs aimed at the development of an affinity purification procedure, and the mAb F8–38 was selected using this technology on the basis of the purification procedure of rFVIII.

[1]  L. Chasin,et al.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Josić,et al.  Peptide affinity chromatography of human clotting factor VIII. Screening of the vWF-binding domain. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[3]  A. Dorner,et al.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. , 1988, The Journal of biological chemistry.

[4]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[5]  A. Giles,et al.  Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. , 1993, Blood.

[6]  P. Hass,et al.  Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. , 1986, Biochemistry.

[7]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[8]  M. Fontaine‐Aupart,et al.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain. , 1991, The Biochemical journal.

[9]  P. Das,et al.  Factor VIII:C assay: influence of buffer components used in immunoaffinity chromatography for purification of factor VIII/von Willebrand factor. , 1994, Thrombosis research.

[10]  A. Goodall,et al.  Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. , 1985, Biochemistry.

[11]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[12]  V. Marder,et al.  Effects of enzymatic degradation on the subunit composition and biologic properties of human factor VIII. , 1978, Blood.

[13]  P. Hass,et al.  Characterization of recombinant human factor VIII. , 1987, The Journal of biological chemistry.

[14]  R. Kaufman,et al.  Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. , 1989, Molecular and cellular biology.

[15]  J. H. Wang,et al.  Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII. , 1992, Biochemistry.

[16]  H. de la Salle,et al.  Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII delta II. , 1991, European journal of biochemistry.

[17]  Denis Drapeau,et al.  Spin Filter Perfusion System for High Density Cell Culture: Production of Recombinant Urinary Type Plasminogen Activator in CHO Cells , 1990, Bio/Technology.

[18]  Bo Johnsson,et al.  A novel hydrogel matrix on gold surfaces in surface plasmon resonance sensors for fast and efficient covalent immobilization of ligands , 1990 .

[19]  C. Prowse,et al.  Immunoaffinity Purification of Factor VIII Complex , 1987, Thrombosis and Haemostasis.

[20]  Z. Yu,et al.  Surface plasmon resonance (SPR) as a tool for antibody conjugate analysis. , 1999, Bioconjugate chemistry.

[21]  Soo-Young Lee,et al.  Continuous stable production of von Willebrand Factor monoclonal antibody in spin filter bioreactor with bleeding technology , 2000 .

[22]  Y. Tajima,et al.  Efficient production of recombinant human factor VIII by co-expression of the heavy and light chains. , 1993, Protein engineering.

[23]  J. Severs,et al.  Characterization of tyrosine sulfate residues in antihemophilic recombinant factor VIII by liquid chromatography electrospray ionization tandem mass spectrometry and amino acid analysis. , 1999, Rapid communications in mass spectrometry : RCM.

[24]  P. Schuck,et al.  Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. , 1997, Annual review of biophysics and biomolecular structure.

[25]  K. Alfthan,et al.  Surface plasmon resonance biosensors as a tool in antibody engineering. , 1998, Biosensors & bioelectronics.

[26]  B. Keyt,et al.  Expression of active human factor VIII from recombinant DNA clones , 1984, Nature.

[27]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[28]  Magnus Malmqvist,et al.  Biospecific interaction analysis using biosensor technology , 1993, Nature.